Physiological SCFA elevation may generate a weak, context-dependent signal that is insufficient alone but could become beneficial when paired with a clinically stronger pathway such as GLP-1 receptor agonism or with suppression of inflammasome activation. This is a viable research strategy, although a positive combination result would not by itself prove that SCFAs directly enhance alpha-synuclein clearance.
Curated pathway from expert analysis
flowchart TD
A["Target Gene: GLP1R/NLRP3"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for GLP1R/NLRP3 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GLP1R.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF physiological-dose SCFA mixture (sodium propionate 20mM, sodium butyrate 10mM, sodium acetate 30mM in drinking water for 12 weeks) is co-administered with a GLP-1R agonist (liraglutide 30 nmol/kg t | ≥20% reduction in striatal pSer129 alpha-synuclein pathology and ≥15% improvement in rotarod latency to fall compared to GLP-1R agonist monotherapy | — no observation — | pending | 0.65 |
| IF physiological-dose SCFA mixture (sodium propionate 20mM, sodium butyrate 10mM, sodium acetate 30mM in drinking water for 8 weeks) is co-administered with an NLRP3 inhibitor (MCC950 10 mg/kg daily, | ≥25% reduction in cortical caspase-1 fluorometric activity and ≥20% improvement in Y-maze spontaneous alternation percentage compared to MCC950 monotherapy | — no observation — | pending | 0.58 |